GT Biopharma, Inc. - FORM 10-Q - EX-32.2 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - November 14, 2017

Attached files

file filename
10-Q - QUARTERLY REPORT - GT Biopharma, Inc.gtbp_10q.htm
EX-32.1 - CERTIFICATE PURSUANT TO SECTION 18 U.S.C. PURSUANT TO SECTION 906 OF THE SARBANE - GT Biopharma, Inc.gtbp_ex321.htm
EX-31.2 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex312.htm
EX-31.1 - CERTIFICATION PURSUANT TO RULE 13A-14(A)/15D-14(A) CERTIFICATIONS SECTION 302 OF - GT Biopharma, Inc.gtbp_ex311.htm
EX-10.10 - AMENDED PREFERRED CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-10.htm
EX-10.9 - AMENDED WARRANT CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-9.htm
EX-10.8 - AMENDED NOTE CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-8.htm
EX-10.7 - PREFERRED CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-7.htm
EX-10.6 - WARRANT CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-6.htm
EX-10.5 - NOTE CONVERSION AGREEMENT - GT Biopharma, Inc.gtbp_ex10-5.htm
EX-10.4 - EMPLOYMENT AGREEMENT WITH DR. RAYMOND URBANSKI - GT Biopharma, Inc.gtbp_ex10-4.htm
EX-10.3 - EMPLOYMENT AGREEMENT WITH STEVEN WELDON - GT Biopharma, Inc.gtbp_ex10-3.htm
EX-10.2 - EMPLOYMENT AGREEMENT WITH DR. KATHLEEN CLARENCE SMITH - GT Biopharma, Inc.gtbp_ex10-2.htm
EX-10.1 - EMPLOYMENT AGREEMENT WITH ANTHONY CATALDO - GT Biopharma, Inc.gtbp_ex10-1.htm
EX-4.1 - CERTIFICATE OF DESIGNATION OF PREFERENCES, RIGHTS AND LIMITATIONS OF SERIES J CO - GT Biopharma, Inc.gtbp_ex4-1.htm
EX-2.1 - AGREEMENT AND PLAN OF MERGER - GT Biopharma, Inc.gtbp_ex2-1.htm
 
Exhibit 32.2
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
In connection with the Quarterly Report on Form 10-Q of GT Biopharma, Inc. (the “Company”), for the quarterly period ended September 30, 2017, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steven Weldon, Chief Financial Officer of the Company, pursuant to 18 U.S.C. § 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, do hereby certify, to my knowledge that:
 
(1)           The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 15 U.S.C. 78m(a) or 780(d)); and
 
(2)           The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
 
 
 
 
 
Date: November 14, 2017
 
/s/ Steven Weldon
 
 
 
Steven Weldon
 
 
 
CFO, President, Chief Accounting Officer, and Director
 
 
 
 
 
 
A signed original of this written statement required by Section 906 has been provided to GT Biopharma, Inc. and will be retained by GT Biopharma, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
 

Stock widget

Investing forum

GT Biopharma, Inc. Reports